Brinton Pharma appoints Sathya Narayanan as CEO – India Cluster & JPAC

Industry veteran to lead Brinton’s expansion across India and key Asia Pacific markets

LEO Pharma to acquire Timber Pharmaceuticals

The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million

Dupixent is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis

Sanofi Dupixent gets USFDA nod for atopic dermatitis

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood

U.S. FDA approves Leo Pharma’s Adbry

Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022